Salvadori Daniel Gesua Sive 4

What Happened
Daniel Gesua Sive Salvadori, EVP and Group President of Abbott Laboratories (ABT), was granted compensation awards on February 24, 2026. The filing shows: a performance-based restricted stock award of 21,644 shares (acquired at $0) and a derivative award of 89,226 shares (reported at $0) under Abbott’s 2017 Incentive Stock Program. No cash was paid; these are company compensation grants, not open-market purchases or sales.

Key Details

• Transaction date: February 24, 2026; Form 4 filed February 26, 2026 (timely filing).
• Reported price: $0.00 for both the restricted stock award and the derivative award (grant).
• Footnote F1: The 21,644 shares are performance-based restricted stock with a 3-year term; no more than 1/3 may vest each year subject to Abbott meeting a minimum return on equity target. The award allows shares to be withheld for tax purposes.
• Footnote F2: The 89,226-share derivative is an employee stock option granted under the 2017 Incentive Stock Program; it vests/exercises in annual increments of 29,742 on Feb 24 of 2027, 2028 and 2029 and was granted in a transaction exempt from Section 16 under Rule 16b‑3.
• Shares owned after the transaction: not specified in the filing summary provided.

Context
These entries are grants of compensation (restricted stock and options), which are routine for executives and do not represent an open-market buy or sale. Performance RSUs depend on future company performance targets before vesting; the options vest over three years and become exercisable in equal annual tranches. Grants signal expected retention/compensation rather than an immediate view on the stock price.